Mercury Pharmaceuticals

We are de-risking biomedical innovations, while turning biomedical knowledge into social and economic value.

Stay Informed!

Novel embedding-driven AI for adaptable brain control

11

Mar 2026

Novel embedding-driven AI for adaptable brain control

Motor imagery (MI) is the mental process of imagining a specific limb movement, such as raising a hand or walking, without physically performing it. These imagined movements generate distinct patterns of brain activity that can be recorded using electroencephalography (EEG).

A longitudinal guide to early Parkinson’s progression

10

Mar 2026

A longitudinal guide to early Parkinson’s progression

Critical Path Institute® (C-Path) applauds the publication of a new study in the Journal of Neurology that offers critical longitudinal insights into how symptoms and functional impacts evolve for individuals with early Parkinson's disease (PD).

New review reveals complex polygenic architecture underlying common epilepsies

10

Mar 2026

New review reveals complex polygenic architecture underlying common epilepsies

An insightful mini-review published in Genomic Psychiatry synthesizes the rapidly expanding landscape of molecular genetic research on common epilepsies, assembling evidence from genome-wide association studies, whole-exome sequencing projects, and advanced statistical modeling to illuminate the polygenic architecture that underpins these heterogeneous neurological disorders.

Wegovy linked to higher risk of eye stroke and vision loss

10

Mar 2026

Wegovy linked to higher risk of eye stroke and vision loss

Wegovy, a GLP-1 agonist for weight loss, may carry the highest risk of 'eye stroke' (ischemic optic neuropathy) and sudden sight loss of the semaglutide drugs, finds an analysis of unintended side effect reports published in the British Journal of Ophthalmology.

MERCURY trials

Clinical trials are very important as it allow us to evaluate the effectiveness of new drugs, new devices, preventative strategies or treatment strategies. It also enables us to discover better ways for patients' care.
- Learn more

Cancer

Our mission remains constant as we endeavor to deliver novel medicines to patients with cancer, treating solid tumors with high unmet medical needs in well-defined patient populations that are currently not well supported.
- Learn more

Neuroscience

Whether you're looking to manufacture toxicology batches or cGMP material for clinical trials, we can help you expedite molecules to clinic with full transparency.
- Learn more

Mercury Pharmaceuticals

Why Us?

Strong experience in academic research and technology transfer makes us understand your goals and motivations as a technology originator.
Our experience in drug development from discovery to clinical and commercial stages makes us an insider player within the biopharmaceutical industry.
Smart approach to project management that helps speed up development stages and decision making.
Availability of own investment up to 2m€ per project allows us to reach the next value milestone.